Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565333 | 0.92 | ACE (0.49) | ALDH1A1TSHRSMN1; SMN2ACEL3MBTL1 | |
| SCHEMBL12999350 | 0.81 | HDAC1 (0.54) | SRC | |
| SCHEMBL7371673 | 0.81 | ITGB3 (0.51) | ALDH1A1ACEKDM4EKMT2AL3MBTL1 | |
| SCHEMBL3288909 | 0.80 | HDAC1 (0.51) | ACE | |
| SCHEMBL2566024 | 0.73 | HDAC1 (0.53) | — | |
| SCHEMBL8619188 | 0.73 | HRH3 (0.38) | ALDH1A1SRCKDM4EL3MBTL1GAA | |
| SCHEMBL7337541 | 0.73 | TBXAS1 (0.47) | ACE | |
| SCHEMBL28747644 | 0.73 | CHRNB4 (0.62) | KDM4EKMT2A | |
| SCHEMBL17117358 | 0.73 | SIGMAR1 (0.56) | — | |
| SCHEMBL2563898 | 0.72 | HDAC1 (0.56) | ACEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626961-B1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2011-11-02 | — | — | EP | claimed |
| JP-4799408-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-20100286207-A1 | Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-11-11 | — | — | US | claimed |
| EP-1626961-A4 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2008-07-16 | — | — | EP | claimed |
| US-20070167486-A1 | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | US | claimed |
| JP-2007501855-A | — | — | 2007-02-01 | — | — | JP | claimed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | claimed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | claimed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | claimed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | claimed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | claimed |
| EP-1626961-B1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2011-11-02 | — | — | EP | disclosed |
| US-7846963-B2 | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-12-07 | — | — | US | disclosed |
| US-20100286207-A1 | Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-11-11 | — | — | US | disclosed |
| US-7723376-B2 | 2-oxo-heterocyclic compounds and pharmaceutical compositions | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | disclosed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | disclosed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286207-A1 | Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same | NOD2, BMP2, NOD1 | ALDH1A1 1362/4885TSHR 3661/4885SMN1; SMN2 149/4885 |
| US-20070167486-A1 | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | NOD2, NOD1, BMP2 | ALDH1A1 1329/4885TSHR 3569/4885SMN1; SMN2 137/4885 |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | MALT1, BRCA1, MCL1 | ALDH1A1 519/4885TSHR 2470/4885SMN1; SMN2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.